Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

Market Cap	5.80B +43.1%
Revenue (ttm)	917.99M +10.9%
Net Income	168.68M +293.1%
EPS	1.06 +285.2%
Shares Out	157.53M
PE Ratio	34.72
Forward PE	32.56
Dividend	0.35 (0.96%)
Ex-Dividend Date	Jun 9, 2025

Volume	4,952,430
Average Volume	3,257,888
Open	36.26
Previous Close	36.38
Day's Range	35.85 - 37.88
52-Week Range	28.13 - 67.98
Beta	0.47
RSI	49.14
Earnings Date	Apr 23, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 668
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603590

Financial Performance

In 2025, SHA:603590's revenue was 915.12 million, an increase of 10.87% compared to the previous year's 825.40 million. Earnings were 165.97 million, an increase of 293.13%.